Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
BioLineRx Ltd. BLRX
$1.53
-$0.11 (-7.27%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
102140796.00000000
-
week52high
1.98
-
week52low
0.55
-
Revenue
0
-
P/E TTM
-8
-
Beta
1.32182300
-
EPS
-0.45000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 04:00
Описание компании
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 23 февр 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 16 дек 2020 г. |
| Oppenheimer | Outperform | 25 ноя 2020 г. | |
| Maxim Group | Buy | Hold | 25 ноя 2020 г. |
| Oppenheimer | Outperform | 04 авг 2017 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
The 3 Best Biotech Stocks Under $1 to Buy for April
InvestorPlace
04 апр 2023 г. в 20:21
Typically, penny stocks are pure market wages for hardened gamblers. In fact, penny stocks are always risky — especially some of the best biotech stocks under $1 – and should oftentimes be avoided.
BioLineRx Ltd. (BLRX) Q4 2022 Earnings Call Transcript
Seeking Alpha
22 мар 2023 г. в 15:22
BioLineRx Ltd. (NASDAQ:BLRX ) Q4 2022 Earnings Conference Call March 22, 2023 10:00 AM ET Company Participants John Lacey - Investor Relations Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Holly May - Chief Commercial Officer Ella Sorani - Chief Development Officer Conference Call Participants Mark Breidenbach - Oppenheimer Joe Pantginis - Wainwright John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by.
BioLineRx Ltd. (BLRX) Q3 2022 Earnings Call Transcript
Seeking Alpha
15 ноя 2022 г. в 15:11
BioLineRx Ltd. (NASDAQ:BLRX ) Q3 2022 Earnings Conference Call November 15, 2022 10:00 AM ET Company Participants John Lacey - IR Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Holly May - Chief Commercial Officer Abi Vainstein-Haras - Chief Medical Officer Conference Call Participants Joe Pantginis - H.C.
BioLineRx Ltd. (BLRX) CEO Philip Serlin on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
16 авг 2022 г. в 13:00
BioLineRx Ltd. (NASDAQ:BLRX ) Q2 2022 Earnings Conference Call August 16, 2022 10:00 AM ET Company Participants Tim McCarthy - LifeSci Advisors, IR Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Holly May - Chief Commercial Officer Conference Call Participants Joe Pantginis - H.C.